Clinic Roundup

 EntreMed Inc., of Rockville, Md., said it started a Phase II study, titled "A Phase II Study of Oral ENMD-2076 Administered to Patients with Advanced/Metastatic Soft Tissue Sarcoma." ENMD-2076 is designed to inhibit both Aurora kinase A and angiogenesis.